Rate vs rhythm control in new-onset AF with HFpEF: post-EAST-AFNET 4 practice?

72F with HFpEF (EF 58%, grade II diastolic dysfunction) presenting with new-onset atrial fibrillation, ventricular rate 128. Symptom duration approximately 72 hours. She is hemodynamically stable but symptomatic (dyspnea on exertion, palpitations, fatigue).

Prior to the EAST-AFNET 4 trial, I would have been comfortable with rate control alone. Post-EAST-AFNET 4, early rhythm control showed cardiovascular benefit.

Questions:

Has EAST-AFNET 4 changed your practice for new-onset AF in the elderly with HFpEF?
If rhythm control, which antiarrhythmic? Amiodarone vs flecainide vs sotalol in HFpEF?
Role of early catheter ablation in this demographic?
Anticoagulation: CHA2DS2-VASc score is 4 (age, female, heart failure, hypertension). DOAC initiation timing relative to cardioversion?

EAST-AFNET 4 was a practice-changing trial for me. Here is how I apply it:

1. Has it changed my practice? Yes. EAST-AFNET 4 showed that early rhythm control (within 12 months of AF diagnosis) reduced the composite of cardiovascular death, stroke, and hospitalization for worsening heart failure. The benefit was consistent across subgroups, including patients > 65 and those with heart failure.

2. Antiarrhythmic choice in HFpEF: This is where it gets nuanced.

Flecainide is my first choice IF there is no significant LVH and no structural heart disease beyond diastolic dysfunction. It has excellent efficacy for AF maintenance.
Amiodarone if there is significant LVH (septum > 14mm) or if the patient has coronary artery disease. Amiodarone is the only antiarrhythmic that is safe in essentially all cardiac substrates, but the long-term toxicity profile makes it a second-line agent.
I avoid sotalol in patients > 70 due to QT prolongation risk and proarrhythmia, especially with age-related renal decline affecting drug clearance.

3. Catheter ablation: The CASTLE-AF trial showed mortality benefit for ablation in HFrEF, but evidence in HFpEF is less robust. In a 72-year-old with HFpEF, I would trial antiarrhythmic pharmacotherapy first and reserve ablation for drug failure or intolerance. The CABANA trial subgroup analysis suggested benefit in patients < 65 but not convincingly in older populations.

4. Anticoagulation timing: With CHA2DS2-VASc of 4, start apixaban 5mg BID (or 2.5mg BID if she meets dose-reduction criteria for age + weight or age + creatinine) immediately upon diagnosis, regardless of cardioversion timing. If cardioversion is planned, it can be performed after 3 weeks of therapeutic anticoagulation or earlier with TEE-guided approach.

From the internist's perspective managing these patients on the ward, I want to add the practical rate control approach for when rhythm control is deferred or pending cardiology review:

Diltiazem is my preferred rate control agent in HFpEF. The 2023 AHA guidelines continue to recommend non-dihydropyridine calcium channel blockers for rate control in AF with preserved EF. Metoprolol is an alternative but may worsen exercise capacity in HFpEF.

Target heart rate: < 110 bpm at rest (RACE II trial established lenient rate control as non-inferior to strict control). In practice, most patients feel better at HR < 90, so I aim for that if tolerated.

One practical tip: before cardioversion, always check TSH. Hyperthyroidism causes AF in 2 to 5% of new presentations, and cardioversion will fail if the underlying cause is not addressed.

2 Answers